Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of February 2020. The report details a completed private placement offering that closed on February 12, 2020, following a Securities Purchase Agreement entered into on February 10, 2020.
Key Financial Metrics
- Net Proceeds: Approximately $4.2 million (assuming full exercise of Pre-funded Warrants and excluding proceeds from Warrant exercises).
- Offering Structure:
- 1,825,000 Units sold at $1.50 per Unit (each Unit includes one ADS and one Warrant).
- 1,508,334 Pre-funded Units sold at $1.49 per Pre-funded Unit (each includes one Pre-funded Warrant and one Warrant).
- Transaction Costs:
- Placement Agent Cash Fee: 7.5% of gross proceeds.
- Management Fee: 1% of gross proceeds.
- Non-accountable expenses: $50,000.
- Legal fee reimbursement: $100,000.
- Closing fees: $12,900.
- Placement Agent Warrants: 250,000 warrants exercisable at $1.875 per ADS, expiring February 10, 2025.
Material Changes
The filing does not provide comparative financial data (revenue, profit, or cash flow) for the prior period. The primary material change is the increase in capitalization and potential dilution resulting from the issuance of new ADSs and warrants. The Pre-funded Units were utilized to allow investors to participate without exceeding beneficial ownership thresholds of 4.99% or 9.99%.
Guidance, Outlook, and Restrictions
- Lock-up Periods: The Company agreed not to enter into "variable rate transactions" for 6 months following the closing. Additionally, the Company is restricted from issuing or announcing the issuance of ADSs or ordinary shares for 30 days post-closing, subject to exceptions.
- Warrant Terms: Warrants included in the Units and Pre-funded Units are immediately exercisable at $1.50 per ADS and expire five years from issuance. Pre-funded Warrants are immediately exercisable at $0.001 per share.
- Management Commentary: The filing states that the Purchase Agreement provisions are not intended as factual information for the public and directs investors to other SEC filings for the current state of affairs.
Investor Verification Checklist
- Verify the full exercise of Pre-funded Warrants to confirm the $4.2 million net proceeds figure.
- Review the Company's latest Form 20-F for baseline financial metrics (cash position, debt, and operating expenses) to assess the impact of the new capital.
- Confirm the dilution impact on existing shareholders given the issuance of approximately 3.3 million new securities (Units and Pre-funded Units) plus Placement Agent warrants.
- Monitor compliance with the 30-day and 6-month issuance restrictions outlined in the Purchase Agreement.